Your browser doesn't support javascript.
loading
Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann, N; Robausch, M; Rosian, K; Wild, C; Simon, J.
Afiliación
  • Grössmann N; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria; Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. Electronic address: nicole.groessmann@hta.lbg.ac.at.
  • Robausch M; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria; Austria and Lower Austrian Sickness Fund, St. Pölten, Austria.
  • Rosian K; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
  • Wild C; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
  • Simon J; Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Applied Diagnostics, Vienna, Austria.
Eur J Cancer ; 110: 1-7, 2019 03.
Article en En | MEDLINE | ID: mdl-30735832
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aprobación de Drogas / Neoplasias / Antineoplásicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aprobación de Drogas / Neoplasias / Antineoplásicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article